Compare NOTV & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NOTV | IXHL |
|---|---|---|
| Founded | 1974 | 2001 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.9M | 49.1M |
| IPO Year | 1997 | N/A |
| Metric | NOTV | IXHL |
|---|---|---|
| Price | $0.67 | $0.42 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $3.00 | N/A |
| AVG Volume (30 Days) | 1.6M | ★ 24.9M |
| Earning Date | 02-04-2026 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $513,024,000.00 | $12,000.00 |
| Revenue This Year | $6.26 | N/A |
| Revenue Next Year | $45.49 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 4.54 | N/A |
| 52 Week Low | $0.66 | $0.08 |
| 52 Week High | $6.48 | $2.25 |
| Indicator | NOTV | IXHL |
|---|---|---|
| Relative Strength Index (RSI) | 30.65 | 52.82 |
| Support Level | $0.79 | $0.38 |
| Resistance Level | $0.86 | $0.45 |
| Average True Range (ATR) | 0.07 | 0.04 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 6.69 | 47.53 |
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.